BR112022017110A2 - Composições e uso das mesmas - Google Patents
Composições e uso das mesmasInfo
- Publication number
- BR112022017110A2 BR112022017110A2 BR112022017110A BR112022017110A BR112022017110A2 BR 112022017110 A2 BR112022017110 A2 BR 112022017110A2 BR 112022017110 A BR112022017110 A BR 112022017110A BR 112022017110 A BR112022017110 A BR 112022017110A BR 112022017110 A2 BR112022017110 A2 BR 112022017110A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- prevention
- management
- treatment
- inflammatory bowel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
COMPOSIÇÕES E USO DAS MESMAS. A presente invenção refere-se a composições terapêuticas compreendendo um inibidor de PDE10A para uso na prevenção, manejo e/ou tratamento de doenças inflamatórias intestinais e, particularmente, para uso em indivíduos que sofrem de colite ulcerativa.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2002926.0A GB202002926D0 (en) | 2020-02-28 | 2020-02-28 | Compositions and uses thereof |
PCT/GB2021/050498 WO2021171035A1 (en) | 2020-02-28 | 2021-02-26 | Compositions and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022017110A2 true BR112022017110A2 (pt) | 2022-11-16 |
Family
ID=70278604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022017110A BR112022017110A2 (pt) | 2020-02-28 | 2021-02-26 | Composições e uso das mesmas |
Country Status (17)
Country | Link |
---|---|
US (1) | US20230149385A1 (pt) |
EP (1) | EP4103161B1 (pt) |
JP (1) | JP2023515551A (pt) |
KR (1) | KR20220154133A (pt) |
CN (1) | CN115484938A (pt) |
AU (1) | AU2021227457A1 (pt) |
BR (1) | BR112022017110A2 (pt) |
CA (1) | CA3169489A1 (pt) |
DK (1) | DK4103161T3 (pt) |
FI (1) | FI4103161T3 (pt) |
GB (1) | GB202002926D0 (pt) |
HR (1) | HRP20240236T1 (pt) |
LT (1) | LT4103161T (pt) |
MX (1) | MX2022010561A (pt) |
PT (1) | PT4103161T (pt) |
RS (1) | RS65259B1 (pt) |
WO (1) | WO2021171035A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB202110990D0 (en) * | 2021-07-30 | 2021-09-15 | Benevolentai Cambridge Ltd | Organic compound and their uses |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1841757B1 (en) | 2005-01-07 | 2010-06-30 | Pfizer Products Incorporated | Heteroaromatic quinoline compounds and their use as pde10 inhibitors |
NL2000397C2 (nl) | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
WO2008001182A1 (en) | 2006-06-26 | 2008-01-03 | Pfizer Products Inc. | Tricyclic heteroaryl compounds as pde10 inhibitors |
WO2008032171A1 (en) * | 2006-09-11 | 2008-03-20 | Matrix Laboratories Ltd. | Dibenzofuran derivatives as inhibitors of pde-4 and pde-10 |
EP3006031A1 (en) | 2009-02-05 | 2016-04-13 | Takeda Pharmaceutical Company Limited | Pyridazinone compounds |
TWI481607B (zh) * | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為pde10a酵素抑制劑的2-芳基咪唑衍生物 |
JP5800813B2 (ja) | 2010-08-04 | 2015-10-28 | 武田薬品工業株式会社 | 複素環化合物 |
JP2014122161A (ja) | 2011-03-31 | 2014-07-03 | Astellas Pharma Inc | ピラゾール化合物 |
US9579407B2 (en) | 2011-08-22 | 2017-02-28 | Takeda Pharmaceutical Company Limited | Radiolabeled compounds and their use as radiotracers for quantitative imaging of phosphodiesterase (PDE10A) in mammals |
US9138494B2 (en) | 2011-12-23 | 2015-09-22 | Abbvie Inc. | Radiolabeled PDE10A ligands |
US9790203B2 (en) | 2012-11-26 | 2017-10-17 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
WO2015006689A1 (en) * | 2013-07-12 | 2015-01-15 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression |
BR112017006272A2 (pt) * | 2014-09-29 | 2018-03-13 | Ea Pharma Co., Ltd. | composição farmacêutica para tratar colite ulcerativa. |
AU2017366515B2 (en) * | 2016-11-24 | 2021-01-21 | Ganzhou Hemay Pharmaceutical, Co., Ltd | Piperidine-2,6-diketone derivative and treatment for Crohn's disease |
WO2019079647A2 (en) * | 2017-10-18 | 2019-04-25 | Wuxi Nextcode Genomics Usa, Inc. | IA STATISTICS FOR DEEP LEARNING AND PROBABILISTIC PROGRAMMING, ADVANCED, IN BIOSCIENCES |
-
2020
- 2020-02-28 GB GBGB2002926.0A patent/GB202002926D0/en not_active Ceased
-
2021
- 2021-02-26 EP EP21709784.9A patent/EP4103161B1/en active Active
- 2021-02-26 CN CN202180031469.XA patent/CN115484938A/zh active Pending
- 2021-02-26 PT PT217097849T patent/PT4103161T/pt unknown
- 2021-02-26 CA CA3169489A patent/CA3169489A1/en active Pending
- 2021-02-26 HR HRP20240236TT patent/HRP20240236T1/hr unknown
- 2021-02-26 KR KR1020227033569A patent/KR20220154133A/ko unknown
- 2021-02-26 AU AU2021227457A patent/AU2021227457A1/en active Pending
- 2021-02-26 LT LTEPPCT/GB2021/050498T patent/LT4103161T/lt unknown
- 2021-02-26 US US17/802,949 patent/US20230149385A1/en active Pending
- 2021-02-26 JP JP2022551009A patent/JP2023515551A/ja active Pending
- 2021-02-26 BR BR112022017110A patent/BR112022017110A2/pt unknown
- 2021-02-26 MX MX2022010561A patent/MX2022010561A/es unknown
- 2021-02-26 WO PCT/GB2021/050498 patent/WO2021171035A1/en active Application Filing
- 2021-02-26 RS RS20240256A patent/RS65259B1/sr unknown
- 2021-02-26 DK DK21709784.9T patent/DK4103161T3/da active
- 2021-02-26 FI FIEP21709784.9T patent/FI4103161T3/fi active
Also Published As
Publication number | Publication date |
---|---|
JP2023515551A (ja) | 2023-04-13 |
DK4103161T3 (da) | 2024-03-11 |
FI4103161T3 (fi) | 2024-02-29 |
AU2021227457A1 (en) | 2022-10-20 |
HRP20240236T1 (hr) | 2024-04-26 |
RS65259B1 (sr) | 2024-03-29 |
EP4103161A1 (en) | 2022-12-21 |
KR20220154133A (ko) | 2022-11-21 |
EP4103161B1 (en) | 2023-12-20 |
LT4103161T (lt) | 2024-03-12 |
CN115484938A (zh) | 2022-12-16 |
PT4103161T (pt) | 2024-03-11 |
CA3169489A1 (en) | 2021-09-02 |
MX2022010561A (es) | 2022-11-30 |
WO2021171035A1 (en) | 2021-09-02 |
US20230149385A1 (en) | 2023-05-18 |
GB202002926D0 (en) | 2020-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021000382A1 (es) | Compuestos novedosos de sulfonamidaurea | |
BR112016027041A8 (pt) | combinações farmacêuticas para tratamento do câncer | |
BR112016020199A8 (pt) | composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
BR112022012637A2 (pt) | Composto de piridazinil-tiazolcarboxamida, composição farmacêutica e inibidor da dgk ¿ que compreendem o mesmo e uso do dito composto para tratar câncer relacionado à ativação das células imunes ou câncer tendo resistência à terapia com anticorpo anti-pd-1 / anticorpo anti-pd-l1 | |
CL2013000304A1 (es) | Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor. | |
BRPI1009842B8 (pt) | uso de agonista de tlr9 e agonista de tlr2/6 na preparação de uma composição farmacêutica para tratamento, inibição ou atenuação de uma infecção microbiana, bem como composição farmaceuticamente aceitável compreendendo os referidos agonistas | |
BR112016028446A2 (pt) | inibidor de complemento de ornithodoros moubata para uso no tratamento de doenças mediadas por complemento em pacientes com polimorfismo de c5 | |
BR112014024793A2 (pt) | método de inibição da ativação do complemento dependente de masp-3, e, composição farmacêutica. | |
BR112015022650A8 (pt) | inibidores de quinase induzível por sal macrocíclico. | |
BR112017000285A2 (pt) | métodos de tratamento da profilaxia viral e kits de profilaxia de pré-exposição | |
BR112015019873A2 (pt) | inibidores macrocíclicos da lrrk2 cinase | |
BR112015022982A2 (pt) | inibidores macrocíclicos de rip2 quinase | |
CO2021015622A2 (es) | Terapias de combinación que comprenden inhibidores de apremilast y tyk2 | |
BR112019006880A2 (pt) | compostos e composições para tratamento de leishmaniose e métodos de diagnóstico e tratamen-to usando os mesmos | |
BR112022026186A2 (pt) | Combinação de um inibidor de bromodomínio cbp/p300 e um inibidor de kras | |
BR112022017110A2 (pt) | Composições e uso das mesmas | |
CO2022000270A2 (es) | Inhibidores de enzimas | |
AR112291A1 (es) | Composición para su uso en la prevención y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncológico | |
BR112019002194A2 (pt) | uso de adamts13 para tratar, melhorar e/ou prevenir a crise vaso-oclusiva na doença falciforme, lesão pulmonar aguda e/ou síndrome da insuficiência respiratória aguda | |
BR112019000902A2 (pt) | derivado de oxazina para uso na prevenção da doença de alzheimer em pacientes em risco | |
BR112022014456A2 (pt) | Tafoxiparina para o tratamento da pré-eclâmpsia | |
BR112017007364A2 (pt) | composição farmacêutica para o uso no tratamento ou prevenção de deficiências de vitaminas e minerais em pacientes que foram submetidos à cirurgia de bypass gástrico | |
BR112022011639A2 (pt) | Derivado de indazol e uso do mesmo | |
BR112022019090A2 (pt) | Inibidores de c5a para o tratamento de infecção por coronavírus | |
MA39448A1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical |